|
1
|
Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research.
|
Psychoneuroendocrinology
|
2012
|
3.30
|
|
2
|
Responsiveness to three bronchial provocation tests in patients with asthma.
|
Chest
|
2003
|
1.49
|
|
3
|
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size.
|
J Pharm Sci
|
2006
|
1.18
|
|
4
|
Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length.
|
J Pharm Sci
|
2004
|
1.17
|
|
5
|
In vitro/in vivo comparisons in pulmonary drug delivery.
|
J Aerosol Med Pulm Drug Deliv
|
2008
|
1.15
|
|
6
|
Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy.
|
Int J Pharm
|
2010
|
1.11
|
|
7
|
Formation, characterization, and fate of inhaled drug nanoparticles.
|
Adv Drug Deliv Rev
|
2010
|
1.11
|
|
8
|
Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses.
|
Pharm Res
|
2005
|
1.10
|
|
9
|
How much particle surface corrugation is sufficient to improve aerosol performance of powders?
|
Pharm Res
|
2005
|
1.08
|
|
10
|
In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.
|
AAPS PharmSciTech
|
2007
|
1.07
|
|
11
|
Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes.
|
Am J Respir Crit Care Med
|
2002
|
1.06
|
|
12
|
Pulmonary formulations: what remains to be done?
|
J Aerosol Med Pulm Drug Deliv
|
2010
|
1.05
|
|
13
|
What is a suitable dissolution method for drug nanoparticles?
|
Pharm Res
|
2008
|
1.01
|
|
14
|
Prediction of treatment-response to inhaled corticosteroids by mannitol-challenge test in COPD. A proof of concept.
|
Pulm Pharmacol Ther
|
2004
|
1.00
|
|
15
|
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols.
|
Eur J Pharm Biopharm
|
2008
|
0.98
|
|
16
|
Pulmonary delivery of therapeutic siRNA.
|
Adv Drug Deliv Rev
|
2011
|
0.98
|
|
17
|
Electrostatic charge characteristics of aerosols produced from metered dose inhalers.
|
J Pharm Sci
|
2005
|
0.97
|
|
18
|
The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses.
|
Pharm Res
|
2005
|
0.97
|
|
19
|
Coughing during mannitol challenge is associated with asthma.
|
Chest
|
2004
|
0.95
|
|
20
|
A simple relationship between dielectric constant of mixed solvents with solvent composition and temperature.
|
Int J Pharm
|
2004
|
0.94
|
|
21
|
Liposomal formulations for inhalation.
|
Ther Deliv
|
2013
|
0.94
|
|
22
|
Dissociation in the effect of nedocromil on mannitol-induced cough or bronchoconstriction in asthmatic subjects.
|
Respirology
|
2005
|
0.94
|
|
23
|
The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations.
|
J Pharm Sci
|
2008
|
0.92
|
|
24
|
SPECT Imaging for Radioaerosol Deposition and Clearance Studies.
|
J Aerosol Med
|
2006
|
0.92
|
|
25
|
Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.
|
Pharm Res
|
2007
|
0.91
|
|
26
|
Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler.
|
Pharm Res
|
2007
|
0.91
|
|
27
|
Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems.
|
Pharm Res
|
2010
|
0.90
|
|
28
|
Effect of powder polydispersity on aerosol generation.
|
J Pharm Pharm Sci
|
2002
|
0.89
|
|
29
|
Effect of amino acids on the dispersion of disodium cromoglycate powders.
|
J Pharm Sci
|
2005
|
0.89
|
|
30
|
Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics.
|
Eur J Pharm Biopharm
|
2007
|
0.87
|
|
31
|
Inhaled antibiotics to treat lung infection.
|
Pharm Pat Anal
|
2013
|
0.87
|
|
32
|
Solubility prediction in supercritical CO(2) using minimum number of experiments.
|
J Pharm Sci
|
2002
|
0.87
|
|
33
|
Micro-particle corrugation, adhesion and inhalation aerosol efficiency.
|
Eur J Pharm Sci
|
2008
|
0.86
|
|
34
|
The use of computational approaches in inhaler development.
|
Adv Drug Deliv Rev
|
2011
|
0.86
|
|
35
|
Modifying the release properties of liposomes toward personalized medicine.
|
J Pharm Sci
|
2014
|
0.86
|
|
36
|
Effect of device design on the aerosolization of a carrier-based dry powder inhaler--a case study on Aerolizer(®) Foradile (®).
|
AAPS J
|
2013
|
0.86
|
|
37
|
Sensitivity and validity of three bronchial provocation tests to demonstrate the effect of inhaled corticosteroids in asthma.
|
Chest
|
2003
|
0.86
|
|
38
|
Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies.
|
Int J Mol Sci
|
2011
|
0.84
|
|
39
|
Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
|
Eur J Pharm Sci
|
2010
|
0.84
|
|
40
|
Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines.
|
J Pharm Biomed Anal
|
2009
|
0.84
|
|
41
|
Does the United States Pharmacopeia throat introduce de-agglomeration of carrier-free powder from inhalers?
|
Pharm Res
|
2012
|
0.84
|
|
42
|
Aerosol performance and long-term stability of surfactant-associated liposomal ciprofloxacin formulations with modified encapsulation and release properties.
|
AAPS PharmSciTech
|
2014
|
0.83
|
|
43
|
Can low-dose combination products for inhalation be formulated in single crystalline particles?
|
Eur J Pharm Sci
|
2010
|
0.83
|
|
44
|
Recent advances in controlled release pulmonary therapy.
|
Curr Drug Deliv
|
2009
|
0.83
|
|
45
|
Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI).
|
Eur J Pharm Sci
|
2009
|
0.83
|
|
46
|
The role of particle properties in pharmaceutical powder inhalation formulations.
|
J Aerosol Med
|
2002
|
0.82
|
|
47
|
The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance.
|
J Pharm Sci
|
2007
|
0.82
|
|
48
|
Cospray dried antibiotics for dry powder lung delivery.
|
J Pharm Sci
|
2008
|
0.82
|
|
49
|
Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
|
Int J Pharm
|
2007
|
0.81
|
|
50
|
Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
|
J Aerosol Med Pulm Drug Deliv
|
2013
|
0.80
|
|
51
|
Electrostatics in pharmaceutical aerosols for inhalation.
|
Ther Deliv
|
2013
|
0.80
|
|
52
|
Personalizing aerosol medicine: development of delivery systems tailored to the individual.
|
Ther Deliv
|
2010
|
0.80
|
|
53
|
Preparation and evaluation of controlled release microparticles for respiratory protein therapy.
|
J Pharm Sci
|
2009
|
0.80
|
|
54
|
Electrostatics of pharmaceutical inhalation aerosols.
|
J Pharm Pharmacol
|
2009
|
0.80
|
|
55
|
Lactose composite carriers for respiratory delivery.
|
Pharm Res
|
2008
|
0.80
|
|
56
|
Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems.
|
J Pharm Sci
|
2011
|
0.80
|
|
57
|
Standardization of techniques for using single-photon emission computed tomography (SPECT) for aerosol deposition assessment of orally inhaled products.
|
J Aerosol Med Pulm Drug Deliv
|
2012
|
0.80
|
|
58
|
A solid-state NMR study of protein mobility in lyophilized protein-sugar powders.
|
J Pharm Sci
|
2002
|
0.80
|
|
59
|
Impact angles as an alternative way to improve aerosolisation of powders for inhalation?
|
Eur J Pharm Sci
|
2010
|
0.79
|
|
60
|
Constant size, variable density aerosol particles by ultrasonic spray freeze drying.
|
Int J Pharm
|
2012
|
0.79
|
|
61
|
Feasibility of preparing nanodrugs by high-gravity reactive precipitation.
|
Int J Pharm
|
2004
|
0.79
|
|
62
|
Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols.
|
Pharm Res
|
2007
|
0.79
|
|
63
|
Effect of crystallinity on electrostatic charging in dry powder inhaler formulations.
|
Pharm Res
|
2014
|
0.78
|
|
64
|
Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance.
|
J Pharm Sci
|
2011
|
0.78
|
|
65
|
Powder Production and Particle Engineering for Dry Powder Inhaler Formulations.
|
Curr Pharm Des
|
2015
|
0.78
|
|
66
|
The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems.
|
Pharm Res
|
2010
|
0.78
|
|
67
|
Electrostatic charge characteristics of jet nebulized aerosols.
|
J Aerosol Med Pulm Drug Deliv
|
2010
|
0.78
|
|
68
|
Aerosol delivery of nanoparticles in uniform mannitol carriers formulated by ultrasonic spray freeze drying.
|
Pharm Res
|
2013
|
0.78
|
|
69
|
Multi-scale modelling of powder dispersion in a carrier-based inhalation system.
|
Pharm Res
|
2014
|
0.78
|
|
70
|
Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance.
|
J Aerosol Med Pulm Drug Deliv
|
2012
|
0.78
|
|
71
|
Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles.
|
AAPS J
|
2009
|
0.78
|
|
72
|
Solubility prediction of paracetamol in binary and ternary solvent mixtures using Jouyban-Acree model.
|
Chem Pharm Bull (Tokyo)
|
2006
|
0.77
|
|
73
|
Controlled release antibiotics for dry powder lung delivery.
|
Drug Dev Ind Pharm
|
2010
|
0.77
|
|
74
|
Enhanced dissolution of inhalable cyclosporine nano-matrix particles with mannitol as matrix former.
|
Int J Pharm
|
2011
|
0.77
|
|
75
|
Inhalation challenge with bovine dander allergens: who needs it?
|
Chest
|
2003
|
0.77
|
|
76
|
Advances in device and formulation technologies for pulmonary drug delivery.
|
AAPS PharmSciTech
|
2014
|
0.77
|
|
77
|
Preparation of inhalable salbutamol sulphate using reactive high gravity controlled precipitation.
|
J Pharm Sci
|
2008
|
0.77
|
|
78
|
Novel alternatives to reduce powder retention in the dry powder inhaler during aerosolization.
|
Int J Pharm
|
2013
|
0.77
|
|
79
|
TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines.
|
Vaccine
|
2013
|
0.77
|
|
80
|
The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers.
|
Drug Dev Ind Pharm
|
2013
|
0.77
|
|
81
|
Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.
|
Pharm Res
|
2010
|
0.77
|
|
82
|
Method to introduce mannitol powder to intubated patients to improve sputum clearance.
|
J Aerosol Med Pulm Drug Deliv
|
2010
|
0.77
|
|
83
|
Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation.
|
Int J Pharm
|
2006
|
0.77
|
|
84
|
Does electrostatic charge affect powder aerosolisation?
|
J Pharm Sci
|
2010
|
0.76
|
|
85
|
A novel inhalable form of rifapentine.
|
J Pharm Sci
|
2014
|
0.76
|
|
86
|
Pulmonary drug delivery.
|
Ther Deliv
|
2013
|
0.76
|
|
87
|
Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers.
|
Pharm Res
|
2008
|
0.76
|
|
88
|
Nanodrug particles and nanoformulations for drug delivery.
|
Adv Drug Deliv Rev
|
2011
|
0.76
|
|
89
|
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
|
J Pharm Sci
|
2009
|
0.76
|
|
90
|
Generation of fine powders of recombinant human deoxyribonuclease using the aerosol solvent extraction system.
|
Pharm Res
|
2003
|
0.76
|
|
91
|
Evaluation on the use of confined liquid impinging jets for the synthesis of nanodrug particles.
|
Drug Dev Ind Pharm
|
2008
|
0.76
|
|
92
|
The future perspectives of natural materials for pulmonary drug delivery and lung tissue engineering.
|
Expert Opin Drug Deliv
|
2014
|
0.75
|
|
93
|
Unitary hormonal models, peripheral markers, and evaluation of response to drug: a response to Weisman and Feldman.
|
Psychoneuroendocrinology
|
2013
|
0.75
|
|
94
|
Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
|
J Pharm Sci
|
2014
|
0.75
|
|
95
|
The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers.
|
Pharm Res
|
2009
|
0.75
|
|
96
|
NanoXCT: a novel technique to probe the internal architecture of pharmaceutical particles.
|
Pharm Res
|
2014
|
0.75
|
|
97
|
Modeling the entrainer effects on solubility of solutes in supercritical carbon dioxide.
|
Chem Pharm Bull (Tokyo)
|
2005
|
0.75
|
|
98
|
Mathematical representation of apparent dissociation constants in aqueous-organic solvent mixtures.
|
Int J Pharm
|
2002
|
0.75
|
|
99
|
Effect of mouthpiece washing on aerosol performance of CFC-free Ventolin.
|
J Asthma
|
2004
|
0.75
|
|
100
|
Editorial: Emerging Formulation Design and Drug Delivery Systems for Inhaled Therapy.
|
Curr Pharm Des
|
2015
|
0.75
|
|
101
|
Comparison of different algorithms to calculate electrophoretic mobility of analytes as a function of binary solvent composition.
|
Electrophoresis
|
2003
|
0.75
|
|
102
|
A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.
|
Pharm Res
|
2013
|
0.75
|
|
103
|
Solubility prediction of anthracene in mixed solvents using a minimum number of experimental data.
|
Chem Pharm Bull (Tokyo)
|
2002
|
0.75
|
|
104
|
Dissolution kinetic behavior of drug nanoparticles and their conformity to the diffusion model.
|
Langmuir
|
2008
|
0.75
|
|
105
|
Discrete Modelling of Powder Dispersion in Dry Powder Inhalers - A Brief Review.
|
Curr Pharm Des
|
2015
|
0.75
|
|
106
|
Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
|
Drug Dev Ind Pharm
|
2014
|
0.75
|
|
107
|
Inhalable dry powder formulations of siRNA and pH-responsive peptides with antiviral activity against H1N1 influenza virus.
|
Mol Pharm
|
2015
|
0.75
|
|
108
|
A cosolvency model to predict solubility of drugs at several temperatures from a limited number of solubility measurements.
|
Chem Pharm Bull (Tokyo)
|
2002
|
0.75
|
|
109
|
A novel method for the production of crystalline micronised particles.
|
Int J Pharm
|
2010
|
0.75
|
|
110
|
A unified cosolvency model for calculating solute solubility in mixed solvents.
|
Chem Pharm Bull (Tokyo)
|
2005
|
0.75
|
|
111
|
Isothermal microcalorimetry of pressurized systems I: a rapid method to evaluate pressurized metered dose inhaler formulations.
|
Pharm Res
|
2014
|
0.75
|
|
112
|
Focused-ion-beam milling: a novel approach to probing the interior of particles used for inhalation aerosols.
|
Pharm Res
|
2007
|
0.75
|
|
113
|
Validation of radiolabeling of drug formulations for aerosol deposition assessment of orally inhaled products.
|
J Aerosol Med Pulm Drug Deliv
|
2012
|
0.75
|
|
114
|
Lung deposition of mannitol powder aerosol in healthy subjects.
|
J Aerosol Med
|
2006
|
0.75
|
|
115
|
Isothermal microcalorimetry of pressurized systems II: effect of excipient and water ingress on formulation stability of amorphous glycopyrrolate.
|
Pharm Res
|
2014
|
0.75
|
|
116
|
The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders.
|
Drug Dev Ind Pharm
|
2007
|
0.75
|
|
117
|
Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation.
|
Langmuir
|
2008
|
0.75
|